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The Use of Anti-Libidinal 
Medication with Intellectually 
Disabled Sex Offenders: Client 
Characteristics and Response
Context
Her Majesty’s Prison Whatton
• 840 adult males convicted of a sexual offence
•25% are ID and borderline ID
• Medication commenced in November 2009
• 96 referrals
o Approximately 90% of these receive medication
• Medications used:
o SSRI (Fluoxetine) 
o Anti-androgen (Cyproterone acetate / Androcur)
o GnRH agonist (Triptorelin)
The Evaluation
Mixed method design
•Quantitative components to assess 
effects on sexual preoccupation and 
hypersexuality
•Qualitative component to explore in 
depth experiences of the medication
Sample
• N = 95 referred for meds
• Age 25-80, mean = 45 years (sd=14.7)
• 29.3% of the sample were serving 
determinate sentences 
• 41.4% were serving indeterminate 
sentence for public protection 
• 10.3% were life sentenced offenders 
17.3% were recalled offenders 
• 1.7% were licence revoke
Victims and risk 
• Majority are child offenders 
• Mean RM2000S = high
• RM2000V = medium 
IQ profile
• 32.2 % are considered to have intellectual 
disability or borderline ID 
• 13.8% participants with intellectual disability as 
defined by their IQ score being 69<. 
• 18.4% participants were borderline with their IQ 
scores between 70-79. 
WASI (Weschler Adult Intelligence Scale) or WAIS 
(Weschler Adult Intelligence Scale). 
Possible hypotheses for over 
representation
• Less psychological resources to cope with 
their sexual thoughts and feelings – need 
external mechanism
• They are less inhibited in their self report 
of sexual thoughts and less likely/able to 
evade detection
• Staff perceive them to be less in control 
and more likely to refer 
• They are more sexually preoccupied
Psychometric Measures
• Multiphasic Sex Inventory (MSI) (Nichols & 
Molinder, 1984)   
• Personality Assessment Inventory (PAI) (Morey, 
1991) 
• Severity Indices of Personality Problems (SIPP-
118) (Verheul et al, 2008)
• Sexual Compulsivity Scale (SCS) (Kalichman et 
al, 1994)
• Hospital Anxiety and Depression Scale (HADS) 
(Zigmond & Snaith, 1983) 
Clinical measures
• Frequency of masturbation
• Strength of sexual urges
• Time spent thinking about sex
• Ability to distract from sexual thoughts
• Subjective levels of sexual excitement
Analysis
• The IQ score was used to group 
participants into two categories; lower 
functioning (<79, n= 28 ) and non-lower 
functioning (80>, n = 45 ). 
• First differences between the groups were 
analysed before medication
Level of dysfunction PAI 
• Compared to general population both 
groups showed dysfunction for Anxiety 
Related Disorder, Depression, Mania, 
Schizophrenia, Borderline and Antisocial. 
• Non-ID group showed dysfunction for 
Alcohol.
• ID showed dysfunction for Somatic 
Complaint.
Level of dysfunction
• HADS, SIPP-18, MSI and SCS, neither 
group show dysfunction from the norm 
samples. 
• No difference between the groups on the 
clinical measures
• ID group show signficant difference on the 
MSI Cognitive Distortions and Immaturity 
scale 
Response to treatment
• Measures were analysed 6 months after 
starting medication (<79, n= 7 ) and non-
lower functioning (80> n = 14 ).
• No difference in response to the 
psychometric measures between groups
• Frequency of orgasm – ID group were 
reporting significantly lower frequency
Conclusions
• ID group do not appear to be more 
dysfunctional than non-ID group
• Both groups seem to respond similarly to 
medication with the exception of orgasm 
frequency 
• Detection evasion and level of openness a 
more likely explanation for over 
representation
Participants experiences
Four broad clinical themes emerged:
1. Effects of the medication
2. Compliance and engagement
3. Participant understanding
4. Participant concerns
1. Effects of the medication
Reduced sexual preoccupation and arousal
• Decreased frequency & intensity of sexual 
thoughts, fantasies and urges
• Reduction in arousal and masturbatory 
frequency
• Increased control of sexual thoughts  & ability to 
distract 
• Difficulty in achieving or maintaining an erection 
• Difficulty achieving or delayed ejaculation
1. Effects of the medication
Impulse and emotional control
• Increased ability to recognise inappropriate sexual 
thoughts
I needed just that little bit of extra help
• Improved management of emotions and urges
I kind of like more relaxed, more chilled out but there again I was very bouncy, I was off the wall all the 
time 
• Better subjective control of sexual thoughts
I think I’m always going to have them thoughts there, they are always going to pop in at some stage in 
my, in the day or some, you know, I’m just going to turn around and say ‘don’t want to know’
Side effects
• Tiredness, nausea, headaches and difficulty sleeping
• All short lived or easily overcome
2. Compliance and 
engagement
• Some non-compliance
• Forgetting, wanting to be aroused, avoid side
effects, belief they don’t need them anymore
• Routine / structure is important
All resumed
Future plans
• Some planned to take for life and saw it as an 
impiorant part of risk management
• Others wanted to stop as soon as their licence 
period was up – fear of depdnedy, wanting a 
relationship
3. Participant 
understanding
• Mixed understanding
• Some were not sure how it would effect 
their feritlity
• Therapeutic relationship between 
individuals and staff appears vital in 
providing participants with a safe 
environment to voice and discuss 
their concerns and ask questions
4. Participant concerns
Initial concerns
• Unsure what to expect re. impact and potential side effects
• Lack of control or choice
Continued concerns
• Long term effects – e.g. impact on future sexual
relationships, fertility, becoming dependent, if I will stop
working

Future
• Need to use ID friendly measures
• Different methods for examining clinical 
significance 
